What is the purpose of this study?Acute urethritis (i.e., inflammation of the male urethra) affects millions of men within the United States annually. STI management has proven challenging due to the prevalence of asymptomatic infections and because men often fail to seek STI care until they experience pronounced symptoms. However, even without urethral symptoms, most men with a urethral STI have measurable evidence of urethritis. Thus, a cheap, simple, and non-invasive point of care (POC) test (i.e., results available within 30 minutes) that accurately detects urethritis could be a game changer in STI management as asymptomatic infections could be detected and treated, potentially decreasing the risk of spreading STIs to sexual partners.THIS STUDY IS ENROLLING BY INVITATION ONLY - Patients will be initially identified while in the Bell Flower Clinic (BFC) as someone that meets these criteria: Cisgender men, aged 18 and older, and the reason for visiting BFC is either (1) symptom evaluation or (2) asymptomatic screening and are being tested for GC/CT by urine NAAT. Once identified, a candidate will be contacted directly by IU research staff about study participation.

What is the purpose of this study?The purpose of this study is to look at the effect of oxygen on tumor tissue and cerebrospinal fluid(CSF). Tissue in your body is exposed to less oxygen than is in the air around you. Traditional studies use cells and tissue kept in room air. In this study, we want to mimic what is happening in your body to study the effect on the tumor’s biology. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

What is the purpose of this study?In this 3-phase pilot, we will identify adverse health outcomes and unmet support needs of testicular cancer survivors (TCS) (Phase 1) and employ participatory co-design to adapt an existing acceptance and commitment therapy (ACT)-based intervention with a sample of up to 8 TCS (Phase 2). We will then conduct a single-arm pilot to assess feasibility, acceptability, and preliminary effects of the adapted intervention on fear of cancer recurrence (FCR) and associated outcomes with 20 TCS reporting clinically significant FCR (Phase 3). Our goal is to address a critical gap in the evidence-based care for the growing number of TCS suffering from serious adverse health outcomes, such as FCR. The study currently only includes Phase 1 and 2. Phase 3 will be added at a later date via an amendment. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to establish a recruitment database of individuals who have contacted the research staff in the department of dermatology expressing interest in participating in clinical research and requesting to be contacted if eligible to participate.